quarta-feira, 7 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 30, 2025

Zacks Industry Outlook Highlights Veracyte, IDEXX Laboratories and Intuitive Surgical

View original at finance.yahoo.com
Zacks Industry Outlook Highlights Veracyte, IDEXX Laboratories and Intuitive Surgical For Immediate Release Chicago, IL – December 30, 2025 – Today, Zacks Equity Research discusses Veracyte VCYT, IDEXX Laboratories IDXX and Intuitive Surgical ISRG…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Intuitive Surgical's 2025 EPS consensus estimate is $8.65, representing 17.9% growth year-over-year

    80% confidence
  • The Zacks Medical Instruments industry is trading at a forward 12-month P/E of 30.36X, compared with the broader industry's 21.29X and the S&P 500's 23.42X

    80% confidence
  • Intuitive Surgical's 2025 sales consensus estimate is $9.92 billion, representing 18.7% growth from 2024

    80% confidence
  • Global generative AI in the healthcare market is valued at $2.64 billion in 2025 and is expected to witness a CAGR of 35.2% through 2034

    80% confidence
  • Global growth is expected to remain at 3.2% in 2025 and 3.1% in 2026, below the pre-pandemic average of 3.7%

    80% confidence
  • Veracyte's 2025 EPS consensus estimate is $1.65, representing 38.7% growth from 2024

    80% confidence
  • MedTech deal value surged to $92.8 billion in 2025, the highest level in more than a decade, driven by three mega-deals

    80% confidence
  • Global headline inflation is expected to decline to 4.2% in 2025 and to 3.7% in 2026

    80% confidence
  • Global AI in the healthcare market is projected to witness a CAGR of 44% from 2025 to 2032

    80% confidence
  • The top 50% of Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1

    80% confidence
  • The Medical Instruments industry's five-year P/E range has been as high as 40.76X, as low as 25.73X, with a median of 32.28X

    80% confidence
  • Overall MedTech M&A activity remained below historical norms, with only 46 announced deals through November 30, 2025

    80% confidence
  • Veracyte's 2025 sales consensus estimate is $508.6 million, representing 14.1% growth from 2024

    80% confidence
  • IDEXX Laboratories' 2025 sales consensus estimate is $4.28 billion, representing 9.9% growth

    80% confidence
  • IDEXX Laboratories' 2025 EPS consensus estimate is $12.93, representing 21.2% growth

    80% confidence
  • The Zacks Medical Instruments industry carries a Zacks Industry Rank #161, placing it in the bottom 33% of 243 Zacks industries

    80% confidence
  • Veracyte holds a Zacks Rank #1 (Strong Buy)

    80% confidence
  • IDEXX Laboratories holds a Zacks Rank #2 (Buy)

    80% confidence
  • The application of AI in the diagnostics space is growing enormously, with the market expected to witness a CAGR of 20.4% by 2034

    80% confidence
  • Zacks top stock-picking strategies have averaged gains of +48.4%, +50.2%, and +56.7% per year since 2000, versus the S&P's +7.7% average annual gain

    80% confidence
  • Intuitive Surgical holds a Zacks Rank #2 (Buy)

    80% confidence
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
A nossa leitura dos dados ›
Sinais que acompanhamos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,985
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,985 factos verificados com a fonte5,351 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
Zacks Industry Outlook Highlights Veracyte, IDEXX Laboratories and Intuitive Surgical — Source | Via News | pt.VIA.NEWS